NewsPR Newswire
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
· Published
Article summary
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces...
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…